Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
DEMPDHPCA
DEMPDHPCA is a serotonin 5-HT2 receptor agonist and a cyclized phenethylamine and simplified or partial ergoline that is structurally related to the serotonergic psychedelic lysergic acid diethylamide (LSD). It is the analogue of LSD in which the carbon and nitrogen atoms at positions 1 through 4 of the ergoline ring system have been removed.
DEMPDHPCA produces gross behavioral effects very similar to those of psychedelics like LSD in rodents and has been assumed to act as a hallucinogen likewise. However, the drug has not been tested in humans. DEMPDHPCA is much less potent than LSD in rodents, which was active at a dose of 0.16 μmol/kg by intraperitoneal injection, whereas DEMPDHPCA was active at doses of 10 to 35 μmol/kg. On the other hand, DEMPDHPCA was more potent than dimethyltryptamine (DMT) and is more potent than mescaline.
Like LSD, the drug has been found to act as a potent serotonin 5-HT2A and 5-HT2C receptor agonist in vitro. The affinities (IC50) of the more active enantiomer are in the ranges of 10–100 nM for the serotonin 5-HT2A receptor and 100–1,000 nM for the serotonin 5-HT2C receptor, while its activational potencies (EC50) are less than 100 nM for the serotonin 5-HT2A receptor and in the range of 10–100 nM for the serotonin 5-HT2C receptor. The more active enantiomer of DEIMDHPCA was among the most potent serotonin 5-HT2A receptor agonists of 27 evaluated ergoline-like compounds.
DEMPDHPCA was first described in the scientific literature by Mangner in 1978. It was subsequently patented in 2021 by David E. Olson and colleagues and the patent was assigned to Delix Therapeutics.
A few derivatives of DEMPDHPCA have also been studied and found to produce similar effects and/or amphetamine-like in animals, including the derivatives with 4-methoxy- and 3,4,5-trimethoxy- substitutions on the phenyl ring and the derivative with the phenyl ring replaced with a 1-naphthalene ring. The former two were less potent than DEMPDHPCA, whereas the latter was slightly more potent. Another derivative of DEMPDHPCA, synthesized by David E. Nichols and described in his thesis, is DEMPDHPCA-2C-D, the derivative with 4-methyl and 2,5-dimethoxy substitutions on the phenyl ring.
Hub AI
DEMPDHPCA AI simulator
(@DEMPDHPCA_simulator)
DEMPDHPCA
DEMPDHPCA is a serotonin 5-HT2 receptor agonist and a cyclized phenethylamine and simplified or partial ergoline that is structurally related to the serotonergic psychedelic lysergic acid diethylamide (LSD). It is the analogue of LSD in which the carbon and nitrogen atoms at positions 1 through 4 of the ergoline ring system have been removed.
DEMPDHPCA produces gross behavioral effects very similar to those of psychedelics like LSD in rodents and has been assumed to act as a hallucinogen likewise. However, the drug has not been tested in humans. DEMPDHPCA is much less potent than LSD in rodents, which was active at a dose of 0.16 μmol/kg by intraperitoneal injection, whereas DEMPDHPCA was active at doses of 10 to 35 μmol/kg. On the other hand, DEMPDHPCA was more potent than dimethyltryptamine (DMT) and is more potent than mescaline.
Like LSD, the drug has been found to act as a potent serotonin 5-HT2A and 5-HT2C receptor agonist in vitro. The affinities (IC50) of the more active enantiomer are in the ranges of 10–100 nM for the serotonin 5-HT2A receptor and 100–1,000 nM for the serotonin 5-HT2C receptor, while its activational potencies (EC50) are less than 100 nM for the serotonin 5-HT2A receptor and in the range of 10–100 nM for the serotonin 5-HT2C receptor. The more active enantiomer of DEIMDHPCA was among the most potent serotonin 5-HT2A receptor agonists of 27 evaluated ergoline-like compounds.
DEMPDHPCA was first described in the scientific literature by Mangner in 1978. It was subsequently patented in 2021 by David E. Olson and colleagues and the patent was assigned to Delix Therapeutics.
A few derivatives of DEMPDHPCA have also been studied and found to produce similar effects and/or amphetamine-like in animals, including the derivatives with 4-methoxy- and 3,4,5-trimethoxy- substitutions on the phenyl ring and the derivative with the phenyl ring replaced with a 1-naphthalene ring. The former two were less potent than DEMPDHPCA, whereas the latter was slightly more potent. Another derivative of DEMPDHPCA, synthesized by David E. Nichols and described in his thesis, is DEMPDHPCA-2C-D, the derivative with 4-methyl and 2,5-dimethoxy substitutions on the phenyl ring.